After pilot project, Takeda inks $500M pact to tap into a Kevan Shokat protégé's covalent small molecule fishing platform
As new technologies open up new avenues toward targets widely considered undruggable by small molecules, Takeda is taking a chance on a low-profile drug discovery player with promises of up to $500 million in biobucks.
Over the next two years, Sunnyvale, CA-based BridGene will deploy its chemical proteomics-based platform for five programs against targets of interest, starting with one implicated in neurodegenerative diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.